Rheumatoid arthritis affects about 24.5 million people worldwide as of 2015. Modern medicine still eludes satisfactory cure for this problem. Therefore, world is looking forward for some traditional medicines in this direction. In the present work, therapeutic efficacy of a Unani compound drug Habb-e-Asgand has been evaluated at Regional Research Institute of Unani Medicine (RRIUM), Aligarh, during 2016-2018. A total of 68 patients were selected from the lot of patients attending outpatient department (OPD). The drug Habb-e-Asgand was given 2 tablets for 84 days and results evaluated statistically by one-way analysis of variance (ANOVA) followed by Dennett’s’ test. The results of the present study were evaluated on clinical, biochemical, and haematological parameters have amply demonstrated that the drug Habb-e-Asgand is therapeutically effective in the treatment of Waja ‘al-mafasil (rheumatoid arthritis). The study has also shown the drug non-toxic and safe. Further studies are suggested in large population.

中文翻译：

---

Unani复合药物Habb-e-Asgand在Waja'al-Mafāsil（类风湿关节炎）病例中的疗效和安全性-初步研究

截至2015年，类风湿关节炎影响全球约2450万人。现代医学仍无法令人满意地治愈该问题。因此，世界期待着这一方向的一些传统药物。在当前工作中，2016-2018年间，在阿里加尔的Unani医学区域研究所（RRIUM）评估了Unani复合药物Habb-e-Asgand的治疗功效。从门诊部（OPD）的患者中选择了68名患者。毒品Habb-e-Asgand服用2片，持续84天，并通过单向方差分析（ANOVA），然后进行Dennett检验对结果进行统计学评估。在临床，生化和血液学参数上评估了本研究的结果，充分证明了Habb-e-Asgand药物可有效治疗Waja'al-mafasil（类风湿关节炎）。研究还表明该药无毒安全。建议在大量人群中进行进一步研究。